Cargando…
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732640/ https://www.ncbi.nlm.nih.gov/pubmed/19622156 http://dx.doi.org/10.1186/1471-2407-9-248 |
_version_ | 1782171065457311744 |
---|---|
author | Tölle, Angelika Jung, Monika Lein, Michael Johannsen, Manfred Miller, Kurt Moch, Holger Jung, Klaus Kristiansen, Glen |
author_facet | Tölle, Angelika Jung, Monika Lein, Michael Johannsen, Manfred Miller, Kurt Moch, Holger Jung, Klaus Kristiansen, Glen |
author_sort | Tölle, Angelika |
collection | PubMed |
description | BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma. METHODS: Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ(2)-test), correlations and survival analyses. RESULTS: B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs. CONCLUSION: While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC. |
format | Text |
id | pubmed-2732640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27326402009-08-27 Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? Tölle, Angelika Jung, Monika Lein, Michael Johannsen, Manfred Miller, Kurt Moch, Holger Jung, Klaus Kristiansen, Glen BMC Cancer Research Article BACKGROUND: Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma. METHODS: Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ(2)-test), correlations and survival analyses. RESULTS: B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs. CONCLUSION: While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC. BioMed Central 2009-07-21 /pmc/articles/PMC2732640/ /pubmed/19622156 http://dx.doi.org/10.1186/1471-2407-9-248 Text en Copyright ©2009 Tölle et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tölle, Angelika Jung, Monika Lein, Michael Johannsen, Manfred Miller, Kurt Moch, Holger Jung, Klaus Kristiansen, Glen Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title | Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title_full | Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title_fullStr | Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title_full_unstemmed | Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title_short | Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
title_sort | brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732640/ https://www.ncbi.nlm.nih.gov/pubmed/19622156 http://dx.doi.org/10.1186/1471-2407-9-248 |
work_keys_str_mv | AT tolleangelika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT jungmonika braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT leinmichael braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT johannsenmanfred braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT millerkurt braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT mochholger braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT jungklaus braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer AT kristiansenglen braintypeandlivertypefattyacidbindingproteinsnewtumormarkersforrenalcancer |